Gyroscope Spins Forward With Dry AMD Gene Therapy
Closes $148m Financing
Executive Summary
Fresh cash will help advance the UK firm's one-time investigational gene therapy for geographic atrophy and a listing in the US is in the offing.
You may also be interested in...
Novartis Eyes Gene Therapy Growth With Vedere Acquisition
The Swiss major is paying up to $280m to buy Vedere Bio, which has developed photoreceptor-protein based optogenetic therapies that are delivered to the retina intravitreally to restore vision.
Sobi Ramps Up In Rare Diseases With Apellis Deal
Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.
BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten
Paying $13.1bn for MyoKardia and its potential first-in-class HCM drug, BMS sees a blockbuster sales opportunity that it will grow gradually. MyoKardia team will be absorbed into BMS, Caforio says.